Stockpolly
Search
TVRD · NASDAQ · Biotechnology

Tvardi Therapeutics (TVRD)

Develops oral STAT3 inhibitors for cancer and fibrotic diseases.

$1.89
Pre-market+0.02 (+0.96%)
At close$1.87(+7.16%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue532000300000
Cost of revenue211000000000
Gross profit322000300000
3235317611596877
Research & development252822759064554
777112532223
Selling & marketing000000000000
General & administrative007012532223
Other expenses002000000000
Operating income−29−33−30−7−6−11−2−9−6−8−7−7
10−100−2−3130000
Interest income100010000000
Interest expense002223300000
Other non-operating income−1−1−10−2−10−130000
Income before tax−28−32−31−7−6−13−54−6−7−7−6
Net income from continuing operations−28−32−31−7−6−13−54−6−7−7−6
Net income−28−32−31−7−6−13−54−6−7−7−6
EPS, basic−$18.61−$0.46−$3.28−$13.17−$8.19−$5.04−$0.52$0.51−$0.59−$0.78−$0.73−$0.69
EPS, diluted−$18.61−$0.46−$3.28−$13.17−$8.19−$5.04−$0.52−$1.00−$0.59−$0.78−$0.73−$0.69
Weighted average shares, basic299222989999
Weighted average shares, diluted299222989999
EBITDA−28−32−29−7−4−10−24−6−7−7−7
Depreciation & amortization100000000000
EBIT−28−32−29−7−4−10−24−6−7−7−7